Key result
Heart transplantation is linked to decreased prolargin and MMP-2 in HF, correlating with improved hemodynamics.
Why the study?
Extracellular matrix remodelling is key in heart failure and secondary pulmonary hypertension, but plasma extracellular matrix proteins associated with these conditions and their haemodynamics before and after heart transplantation required identification.
Do plasma levels of prolargin and MMP-2 decrease after heart transplantation and correlate with improved hemodynamics in patients with end-stage heart failure?
Population
26 HF patients and 20 controls
Comparison
HF patients pre-HT and 1 year post-HT vs controls
Follow-up
1 year
Authors
Loading...
Supports prolargin and MMP-2 as potential hemodynamic markers post-transplant; hypothesis-generating for biomarker-guided management in advanced HF.
Observational (n=46)
Do plasma levels of prolargin and MMP-2 decrease after heart transplantation and correlate with improved hemodynamics in patients with end-stage heart failure?
p-value: p=<0.0001
Prolargin and MMP-2 levels are elevated in end-stage heart failure and decrease following heart transplantation, correlating with hemodynamic improvements.
Ahmed et al. (2019) conducted an observational in Heart failure and secondary pulmonary hypertension (n=46). Heart transplantation vs. Controls and pre-transplantation baseline was evaluated on Plasma levels of prolargin and matrix metalloproteinase-2 (MMP-2) (p=<0.0001). Plasma levels of prolargin and MMP-2 were elevated in heart failure patients and decreased significantly 1 year post-heart transplantation (P<0.0001), correlating with improved haemodynamics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: